Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Herishanu, Yair, Avivi, Irit, Aharon, Anat, Shefer, Gabi, Levi, Shai, Bronstein, Yotam, Morales, Miguel, Ziv, Tomer, Shorer Arbel, Yamit, Scarfò, Lydia, Joffe, Erel, Perry, Chava, Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
CLINICAL TRIALS AND OBSERVATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061088/
https://www.ncbi.nlm.nih.gov/pubmed/33861303
http://dx.doi.org/10.1182/blood.2021011568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061088/
https://www.ncbi.nlm.nih.gov/pubmed/33861303
http://dx.doi.org/10.1182/blood.2021011568

Ejemplares similares